We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+8.33%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$16.6M
Cap. Flow
-$8.49M
Cap. Flow %
-4.71%
Top 10 Hldgs %
42.71%
Holding
128
New
34
Increased
5
Reduced
15
Closed
37

Top Buys

Rank Stock Value
1
AVDL
Avadel Pharmaceuticals
AVDL
+$4.11M
2
PEN icon
Penumbra
PEN
+$4.08M
3
ATEC icon
Alphatec Holdings
ATEC
+$3.82M
4
INSP icon
Inspire Medical Systems
INSP
+$3.16M
5
VREX icon
Varex Imaging
VREX
+$3.14M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$6.85M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$6.47M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.29M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$4.95M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 85.22%
2 Financials 3.64%
3 Technology 0.85%
4 Communication Services 0.51%
5 Materials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HYRE
126
DELISTED
HyreCar Inc. Common Stock
HYRE
– –
-1,688,120
Closed -$716K
TGVCU
127
DELISTED
TG Venture Acquisition Corp. Units
TGVCU
– –
-200,000
Closed -$2.04M
RACYW
128
DELISTED
Relativity Acquisition Corp. Warrant
RACYW
$0 ﹤0.01%
100,000
– –
2 3 4 5
6

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Altium Capital Management held 128 positions worth $180M, down 8.5% from $197M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Altium Capital Management withdrew a net $8.49M in Q1 2023, closing 37 positions and reducing 15 holdings. Its most notable exit was Akero Therapeutics, an estimated $6.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Avadel Pharmaceuticals worth $4.58M.

  • Altium Capital Management's largest Q1 2023 buy was Avadel Pharmaceuticals: 500,000 shares worth $4.58M.
  • Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q1 2023, an estimated $2.08M increase.
  • Altium Capital Management's biggest Q1 2023 reduction was PepperLime Health Acquisition Corporation Class A Ordinary Share, cutting an estimated $6.47M.
  • Altium Capital Management fully exited Akero Therapeutics in Q1 2023, selling an estimated $6.85M.
  • Altium Capital Management's ten largest holdings make up 43% of its $180M portfolio in Q1 2023.
  • Altium Capital Management opened 34 new positions and closed 37 in Q1 2023.
  • Altium Capital Management's portfolio value fell 8.5% quarter-over-quarter to $180M.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.